Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB
Mandate

Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB

October 16, 2020

The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EUR 40 million. The loan may be used to further support the clinical development of melflufen and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company. In connection with the loan agreement, Oncopeptides has entered into a warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Viktor Lennartsson.

 

The Swedish rules on cabotage transport and posting will change on 2 and 21 February 2022

 The Swedish government has decided on a number of new rules concerning cabotage transports, combined transports, transport customer responsibility for driving and rest times and posting of workers.
January 21, 2022

Vinge presents the Swedish chapter for the 2022 version of The Legal 500: Private Equity Country Comparative Guide

 The guide provides an overview of the Swedish Private Equity market and the salient legislation in connection with PE transactions in Sweden.
January 11, 2022

The prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings

 On Tuesday 21 December, the EU Court of Justice delivered its long-awaited judgment in the Bank Melli Iran case (Case C-124/20) on the interpretation of the EU Blocking Statute regarding compliance with third country sanctions. According to the Court, the prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings. Following the Court’s judgment, anyone seeking to terminate a contract with a person or business subject to US sanctions must thoroughly consider if the termination is motivated by other reasons than the existing sanctions and reflect on whether to apply to the Commission for a derogation from the Blocking Statute.
December 23, 2021